Page 323 - Binder2

to maintaining product exclusivity long after the original
molecule's patent expires.

But in edible biologics, that paradigm flips completely.
The formulation doesn’t happen after the protein is
made.
It happens as the protein is made—inside the plant.
The plant becomes the bioreactor, the formulator, and the
delivery mechanism all in one. Its cellular machinery
doesn't just produce the protein—it embeds it in a
protective, bioactive matrix that enhances stability, shields
it from degradation, and modulates its immune interaction.
Consider:

● A therapeutic enzyme stored in plant vacuoles
can remain stable for months without refrigeration.
The vacuole acts like a natural encapsulation
chamber—acidic, protease-buffered, and isolated
from degradation pathways.
● Antigens expressed in rice endosperm are
surrounded by starch granules and protein bodies
that shield them from digestive enzymes and low
pH environments in the stomach. This means the
protein reaches the small intestine intact—without
any synthetic coating.

● The entire plant matrix—including fiber, sugars,
and native plant proteins—can act as a slow-release
vehicle. It delays absorption, reduces peak
immunogenicity, and promotes uptake by mucosal
immune cells, gently guiding the immune system
toward tolerance rather than activation.

In traditional pharma, all of these functions would be
achieved through dozens of steps, involving complex
chemistry and millions in formulation development.

321